Early impairment of hepatitis C virus specific I cell proliferation during acute infection leads to failure of viral clearance

Folgori, A.; Spada, E.; Pezzanera, M.; Ruggeri, I.; Mele, A.; Garbuglia, A. R.; Perrone, M. P.; Del Porto, P; Piccolella, E.; Cortese, R.; Nicosia, A.; Vitelli, A.
July 2006
Gut;Jul2006, Vol. 55 Issue 7, p1012
Academic Journal
Background and aims: Cellular mediated immunity (CMI) is thought to play a key role in resolution of primary hepatitis C virus (HCV) infection. However, CD4+ and CD8+ T cell responses are also generated during acute infection in individuals who become chronic, suggesting that they developed a defective CMI. The aim of this study was to verify if and when such immune dysfunction is established by measuring the breadth, magnitude, function, and duration of CMI in a large cohort of subjects during the natural course of acute HCV infection. Methods: CMI was comprehensively studied by prospective sampling of 31 HCV acutely infected subjects enrolled at the onset of infection and followed for a median period of one year. Results: Our results indicated that while at the onset of acute HCV infection a measurable CMI with effector function was detected in the majority of subjects, after approximately six months less than 10% of chronically infected individuals displayed significant CMI compared with 70% of subjects who cleared the virus. We showed that progressive disappearance of HCV specific T cells from the peripheral blood of chronic patients was due to an impaired ability to proliferate that could be rescued in vitro by concomitant exposure to interleukin 2 and the antigen. Conclusion: Our data provide evidence of strong and multispecific T cell responses with a sustained ability to proliferate in response to antigen stimulation as reliable pharmacodynamic measures of a protective CMI during acute infection, and suggest that early impairment of proliferation may contribute to loss of T cell response and chronic HCV persistence.


Related Articles

  • Fibrosis progression in chronic hepatitis C virus infection. McCaughan, G. W.; George, J. // Gut;Mar2004, Vol. 53 Issue 3, p318 

    Chronic hepatitis C virus infection is typically characterised by slowly progressive hepatic fibrosis. However, it is recognised that some patients do not progress while others rapidly develop significant fibrosis. Here, we review studies that have assessed factors that could influence this rate...

  • Immunization with a Recombinant Vaccinia Virus That Encodes Nonstructural Proteins of the Hepatitis C Virus Suppresses Viral Protein Levels in Mouse Liver. Sekiguchi, Satoshi; Kimura, Kiminori; Chiyo, Tomoko; Ohtsuki, Takahiro; Tobita, Yoshimi; Tokunaga, Yuko; Yasui, Fumihiko; Tsukiyama-Kohara, Kyoko; Wakita, Takaji; Tanaka, Toshiyuki; Miyasaka, Masayuki; Mizuno, Kyosuke; Hayashi, Yukiko; Hishima, Tsunekazu; Matsushima, Kouji; Kohara, Michinori // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Chronic hepatitis C, which is caused by infection with the hepatitis C virus (HCV), is a global health problem. Using a mouse model of hepatitis C, we examined the therapeutic effects of a recombinant vaccinia virus (rVV) that encodes an HCV protein. We generated immunocompetent mice that each...

  • Characteristics and PD-1 expression of peripheral CD4+CD127loCD25hiFoxP3+ Treg cells in chronic HCV infected-patients. Tao Shen; Jiajia Zheng; Hua Liang; Chunhui Xu; Xiangmei Chen; Ting Zhang; Qiang Xu; Fengmin Lu // Virology Journal;2011, Vol. 8 Issue 1, p279 

    Background: Both regulatory T cells (Tregs) and PD-1/PD-L1 pathway were critically involved in HCV viral persistence. However, the association between them was not well investigated. Herein, we aimed to investigate the distributional profiles of Tregs subsets and association between PD-1...

  • Cellular Immunity and Acute Hepatitis C Infection. Fitzmaurice, K.; Klenerman, P. // Current Pharmaceutical Design;Jun2008, Vol. 14 Issue 17, p1666 

    Hepatitis C virus (HCV) infects an estimated 170 million people globally and persistent infection within the liver is the usual outcome of infection. The resulting liver disease leads to substantial morbidity and to date no vaccine exists. Furthermore the treatments available are frequently...

  • Topochemical models for predicting the activity of α,γ-diketo acids as inhibitors of the hepatitis c virus NS5B RNA-dependent RNA polymerase. Bajaj, S.; Sambi, S.; Madan, A. // Pharmaceutical Chemistry Journal;Dec2006, Vol. 40 Issue 12, p650 

    A relationship between the topochemical indices of α,γ-diketo acids and their inhibitory activity with respect to the hepatitis C virus NS5b RNA-dependent RNA polymerase has been studied. The values of Wiener’s topochemical index W c (a distance based descriptor), the Zagreb...

  • Cellular Immune Responses during High-Dose Interferon-α Induction Therapy for Hepatitis C Virus Infection. Barnes, Eleanor; Gelderblom, Huub C.; Humphreys, Isla; Semmo, Nasser; Reesink, Henk W.; Beld, Marcel G. H. M.; van Lier, René A. W.; Klenerman, Paul // Journal of Infectious Diseases;3/15/2009, Vol. 199 Issue 6, p819 

    Background. The effect that high-dose interferon (IFN)-α induction therapy for hepatitis C virus (HCV) infection has on cellular immune responses is currently unknown. Methods. Thirty-one treatment-naive patients with chronic HCV infection received amantadine and ribavirin, combined with 6...

  • Unravelling hepatitis C virus replication from genome to function. Lindenbach, Brett D.; Rice, Charles M. // Nature;8/18/2005, Vol. 436 Issue 7053, p933 

    Since the discovery of the hepatitis C virus over 15 years ago, scientists have raced to develop diagnostics, study the virus and find new therapies. Yet virtually every attempt to dissect this pathogen has met with roadblocks that impeded progress. Its replication was restricted to humans or...

  • Hepatitis C Virus (HCV)-Specific T Cell Responses in Injection Drug Users with Apparent Resistance to HCV Infection. Thurairajah, Prem H.; Hegazy, Doha; Chokshi, Shilpa; Shaw, Steve; Demaine, Andrew; Kaminski, Edward R.; Naoumov, Nikolai V.; Cramp, Matthew E. // Journal of Infectious Diseases;12/15/2008, Vol. 198 Issue 12, p1749 

    Background. Injection drug users (IDUs) are at risk of acquiring hepatitis C virus (HCV) infection. We have identified a cohort of long-term IDUs who remain uninfected by HCV despite high-risk behavior. We have categorized these subjects as "exposed uninfected" and have sought immunological...

  • Novel Small-Molecule Inhibitors of Hepatitis C Virus Entry Block Viral Spread and Promote Viral Clearance in Cell Culture. Coburn, Glen A.; Fisch, Danielle N.; Moorji, Sameer M.; Muys, Jean-Marc de; Murga, Jose D.; Paul, Dorothy; Provoncha, Kathleen P.; Rotshteyn, Yakov; Han, Amy Q.; Qian, Dapeng; Maddon, Paul J.; Olson, William C. // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Combinations of direct-acting anti-virals offer the potential to improve the efficacy, tolerability and duration of the current treatment regimen for hepatitis C virus (HCV) infection. Viral entry represents a distinct therapeutic target that has been validated clinically for a number of...


Read the Article


Sign out of this library

Other Topics